European Economic Area

Spark, Novartis’s inherited blindness therapy Luxturna wins approval in Europe

The company expects reimbursement decisions by national-level authorities in 2019 and 2020. The UK's NICE recommended Cancer Drugs Fund coverage for another high-priced Novartis therapy, the CAR-T Kymriah, earlier this month.

By Alaric DeArment

BioPharma, Pharma

Novartis, Spark make positive step toward gene therapy Luxturna’s European approval

With a positive CHMP decision, the European Commission is expected to rule in two months, but equity research analysts foresee significant headwinds for the gene therapy.

By Alaric DeArment